Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06137144 · ClinicalTrials.gov registry record · Phase 1
AZD3470 as Monotherapy and in Combination With Anticancer Agents in Participants With Relapsed/Refractory Haematologic Malignancies.
A Phase 1 study of Lymphoma and Hodgkin Lymphoma, sponsored by AstraZeneca.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 110
- Enrollment target
- 20
- Study locations
NCT06137144: Recruiting Phase 1 study of Lymphoma and Hodgkin Lymphoma, sponsored by AstraZeneca.
NCT06137144 is a Phase 1 study of Lymphoma and Hodgkin Lymphoma that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 110 participants, below the 483-participant average among 299 other Lymphoma trials with a reported enrollment target (77% lower). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06137144, a Phase 1 study of Lymphoma and Hodgkin Lymphoma, is actively recruiting participants, sponsored by AstraZeneca.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 110 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is designed to evaluate the safety, tolerability, PK and preliminary efficacy following oral administration of AZD3470 as a monotherapy, and in combination with other anticancer agents in participants with haematologic malignancies.
Primary Outcome
AEs: Number of patients with adverse events by system organ class and preferred term. SAEs: Number of patients with serious adverse events by system organ class and preferred term.
Conditions Studied
Interventions
- DRUG AZD3470
Study Locations (20)
Other
- Research Site - Nedlands
- Research Site - Créteil
- Research Site - Lille
- Research Site - Pierre-Bénite
- Research Site - Villejuif
- Research Site - Cologne
- Research Site - Alessandria
- Research Site - Bologna
- Research Site - Milan
- Research Site - Seoul
- Research Site - Seoul
- Research Site - L'Hospitalet de Llobregat
- Research Site - Madrid
- Research Site - Manchester
- Research Site - Oxford
Florida
- Research Site - Miami
Georgia
- Research Site - Atlanta
Massachusetts
- Research Site - Boston
Pennsylvania
- Research Site - Philadelphia
Texas
- Research Site - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2024-01-23 |
| Est. Completion | 2026-05-08 |
| Phase | Phase 1 |
What NCT06137144 shows while recruiting
NCT06137144 is an interventional study that assigns participants to a tested intervention. The registered 110 participants enrollment target is mid-sized for trials with a published cap, below the 483-participant average among 299 other Lymphoma trials with a reported enrollment target (77% lower).
The record links to 3 conditions, with Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which AZD3470 is the first listed.
NCT06137144 names 20 study sites across 6 states, led by Other, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT06137144 about?
NCT06137144 is a clinical study titled "AZD3470 as Monotherapy and in Combination With Anticancer Agents in Participants With Relapsed/Refractory Haematologic Malignancies.". This study is designed to evaluate the safety, tolerability, PK and preliminary efficacy following oral administration of AZD3470 as a monotherapy, and in combination with other anticancer agents in participants with haematologic malignancies.
What is the current status of trial NCT06137144?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 110 participants. The study started on 2024-01-23. Estimated completion is 2026-05-08.
What conditions does trial NCT06137144 study?
This clinical trial studies the following conditions: Lymphoma, Hodgkin Lymphoma, Non-Hodgkin.
What interventions are being tested in trial NCT06137144?
The interventions under investigation include: AZD3470 (DRUG).
Who is sponsoring clinical trial NCT06137144?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06137144 being conducted?
This trial has 20 study locations across Florida, Georgia, Massachusetts, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06137144's enrollment target sits among peer trials
110 74th of 299 higher than 226 of 299 other Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma
RECRUITING · Phase 1
-
TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas
RECRUITING · Phase 1
-
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
RECRUITING · Phase 1
-
CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies
RECRUITING · Phase 1
-
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
RECRUITING · Phase 1
-
A Study of TLN-254 in Participants With Relapsed or Refractory T-cell Lymphoma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01530373 · 110 participants · Phase 2
Solifenacin Compared to Clonidine for Reducing Hot Flashes Among Breast Cancer Patients
- NCT02379377 · 110 participants · Phase 1
18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant
- NCT02411773 · 110 participants · Phase 1
Sympatholysis in Chronic Kidney Disease
- NCT03190941 · 110 participants · Phase 1
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI